Production (Stage)
D
Eupraxia Pharmaceuticals Inc. EPRX.TO
TSX
Recommendation
Prev Close
$5.34
Volume
--
Avg Vol (90D)
38,526
Market Cap
$139.97M
Dividend & Yield
--
52-Week Range
$3.07 - $6.49
P/E (TTM)
--
EPS (TTM)
-$0.9836
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% - Should You Sell?
6/6/2025 - MarketBeat
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Update
6/5/2025 - MarketBeat
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ...
6/2/2025 - GuruFocus
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ...
6/2/2025 - GuruFocus
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals
6/2/2025 - TipRanks Financial Blog
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
6/2/2025 - Globe Newswire
Bear-Pit Session Highlights Peterson Capital's Canada Growth Conference in Montreal
5/15/2025 - Globe Newswire
Eupraxia Pharmaceuticals (EPRX) Expected to Announce Quarterly Earnings on Wednesday
5/9/2025 - MarketBeat
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study
5/7/2025 - TipRanks Financial Blog
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of ...
5/7/2025 - GuruFocus
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of ...
5/7/2025 - GuruFocus
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
5/7/2025 - Globe Newswire
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Quarterly Earnings Results
5/7/2025 - Ticker Report
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results EPRX Stock News
5/6/2025 - GuruFocus
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
5/6/2025 - GuruFocus
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
5/6/2025 - TipRanks Financial Blog
Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
5/6/2025 - The Fly
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
5/6/2025 - Globe Newswire
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with ...
5/5/2025 - GuruFocus
Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI
5/5/2025 - TipRanks Financial Blog
Eupraxia Pharmaceuticals announces treatment outcomes for EP-104GI
5/5/2025 - The Fly
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with ...
5/5/2025 - GuruFocus
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
5/5/2025 - Globe Newswire
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
4/24/2025 - GuruFocus
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May ...
4/24/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$34.70M
EBIT (TTM)
-$27.43M
Net Income (TTM)
-$26.22M
Balance Sheet
Total Assets (Q)
$29.23M
Total Debt (Q)
$52.80K
Total Liabilities (Q)
$2.20M
Book Value Per Share (Q)
-$0.0865
Cash Flow
Cash from Operations (TTM)
-$29.88M
Cash from Investing (TTM)
-$237.40K
Cash from Financing (TTM)
$23.06M
Net Change in Cash (TTM)
-$8.45M
Filings
Filing Date
Tuesday, May 6, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
0.87
7-Day Total Return
-5.18%
30-Day Total Return
-3.45%
60-Day Total Return
-6.02%
90-Day Total Return
19.59%
Year to Date Total Return
19.06%
1-Year Total Return
41.60%
2-Year Total Return
-25.94%
3-Year Total Return
369.91%
5-Year Total Return
--
52-week Low
Oct 22, 2024 - $3.07
52-week High
Feb 26, 2025 - $6.49
Valuation
Market Cap
$139.97M - Micro Cap
Enterprise Value
$142.84M
Price/Sales (TTM)
--
Price/Book (Q)
-61.73
Dividends and Shares
Shares Outstanding
35.69M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.eupraxiapharma.com
Phone Number
250-590-3968
Address
2067 Cadboro Bay Road
Victoria, BC V8R 5G4
Country
Canada
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary... more